Viracta Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 12.21 million compared to USD 10.55 million a year ago. Basic loss per share from continuing operations was USD 0.32 compared to USD 0.28 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8283 USD | -2.21% | -3.32% | +45.32% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+45.32% | 32.53M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- VIRX Stock
- News Viracta Therapeutics, Inc.
- Viracta Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023